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Abstract
AIM: To evaluate pretreatment hepatitis B virus (HBV) 
testing, vaccination, and antiviral treatment rates in 
Veterans Affairs patients receiving anti-CD20 Ab for 
quality improvement.
METHODS: We performed a retrospective cohort 
study using a national repository of Veterans Health 
Administration (VHA) electronic health record data. We 
identified all patients receiving anti-CD20 Ab treatment 
(2002-2014). We ascertained patient demographics, 
laboratory results, HBV vaccination status (from 
vaccination records), pharmacy data, and vital status. 
The high risk period for HBV reactivation is during anti-
CD20 Ab treatment and 12 mo follow up. Therefore, 
we analyzed those who were followed to death or 
for at least 12 mo after completing anti-CD20 Ab. 
Pretreatment serologic tests were used to categorize 
chronic HBV (hepatitis B surface antigen positive or 
HBsAg+), past HBV (HBsAg-, hepatitis B core antibody 
positive or HBcAb+), resolved HBV (HBsAg-, HBcAb+, 
hepatitis B surface antibody positive or HBsAb+), likely 
prior vaccination (isolated HBsAb+), HBV negative 
(HBsAg-, HBcAb-), or unknown. Acute hepatitis B was 
defined by the appearance of HBsAg+ in the high 
risk period in patients who were pretreatment HBV 
negative. We assessed HBV antiviral treatment and the 
incidence of hepatitis, liver failure, and death during 
the high risk period. Cumulative hepatitis, liver failure, 
and death after anti-CD20 Ab initiation were compared 
by HBV disease categories and differences compared 
using the χ 2 test. Mean time to hepatitis peak alanine 
aminotransferase, liver failure, and death relative to 
anti-CD20 Ab administration and follow-up were also 
compared by HBV disease group. 
RESULTS: Among 19304 VHA patients who received 
anti-CD20 Ab, 10224 (53%) had pretreatment HBsAg 
testing during the study period, with 49% and 43% 
tested for HBsAg and HBcAb, respectively within 6 mo 
pretreatment in 2014. Of those tested, 2% (167/10224) 
had chronic HBV, 4% (326/7903) past HBV, 5% 
(427/8110) resolved HBV, 8% (628/8110) likely prior 
HBV vaccination, and 76% (6022/7903) were HBV 
negative. In those with chronic HBV infection, ≤ 
37% received HBV antiviral treatment during the high 
risk period while 21% to 23% of those with past or 
resolved HBV, respectively, received HBV antiviral 
treatment. During and 12 mo after anti-CD20 Ab, the 
rate of hepatitis was significantly greater in those HBV 
positive vs  negative (P  = 0.001). The mortality rate was 
35%-40% in chronic or past hepatitis B and 26%-31% 
in hepatitis B negative. In those pretreatment HBV 
negative, 16 (0.3%) developed acute hepatitis B of 
4947 tested during anti-CD20Ab treatment and follow-
up. 
CONCLUSION: While HBV testing of Veterans has 
increased prior to anti-CD20 Ab, few HBV+ patients 
received HBV antivirals, suggesting electronic health 
record algorithms may enhance health outcomes. 
Key words: Hepatitis B; Hepatitis B reactivation; Anti-
CD20 antibody; Rituximab; Lymphoma; Chemotherapy; 
Hepatitis B antivirals; Vaccination; Veteran 
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Prior to anti-CD20 antibody (Ab) treatment 
in 2014, 61%-73% of 19304 Veterans had hepatitis B 
virus (HBV) tests. Of these, 11% tested were positive 
for hepatitis B surface antigen or core antibody and at 
risk for reactivation; ≤ 37% of these HBV+ patients 
received HBV antivirals during anti-CD20 Ab and follow-
up. HBV+ patients had significantly higher hepatitis 
rates than HBV-. Among pretreatment HBV- patients, 
about 1 in 300 tested suffered acute hepatitis during 
anti-CD20 Ab and 12 mo follow-up. Electronic health 
record algorithms to increase HBV testing, antiviral use 
and vaccination will likely improve outcomes with anti-
CD20 Ab treatment. 
Hunt CM, Beste LA, Lowy E, Suzuki A, Moylan CA, Tillmann 
HL, Ioannou GN, Lim JK, Kelley MJ, Provenzale D. Veterans 
health administration hepatitis B testing and treatment with anti-
CD20 antibody administration. World J Gastroenterol 2016; 
22(19): 4732-4740  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i19/4732.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i19.4732
INTRODUCTION
In the United States, 4% of the population has 
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had hepatitis B viral (HBV) infection and 0.3% 
have chronic hepatitis B (with positive hepatitis B 
surface antigen)[1,2]. Following HBV infection, viral 
DNA persists in the liver - though its replication is 
suppressed by B- and T-cells or by HBV antivirals[3,4]. 
With immunosuppression, HBV can reactivate, even in 
patients with past or resolved infection. In untreated 
patients with chronic or prior HBV, nearly 40% of those 
receiving chemotherapy for hematological malignancies 
or solid tumors develop HBV reactivation[5]. HBV 
reactivation frequently interrupts chemotherapy and 
increases cancer mortality[6] by causing hepatitis 
(33%), liver failure (13%) and death (5%)[7]. Use of 
prophylactic HBV antivirals in patients with chronic or 
prior HBV infection largely prevents reactivation[1,7-11]. 
As most patients are asymptomatic and unaware 
of their HBV infection, hepatitis B serology before 
immunosuppression is the most effective means to 
identify the potential for reactivation[12]. Due to a 
higher HBV prevalence in lymphoma patients than the 
general population, HBV reactivation is a particular 
concern in lymphoma[13]. 
Anti-CD20 antibodies (Ab), such as rituximab, 
ofatumumab and obinutuzumab, are common 
treatments for non-Hodgkin’s lymphoma (NHL), chronic 
lymphocytic leukemia (CLL), and rheumatoid arthritis. 
Anti-CD20 Ab act by depleting B-lymphocytes[14]. 
However, anti-CD20 Ab also decrease host immune 
suppression of HBV, potentially leading to viral 
reactivation - identified by increases in HBV DNA and 
alanine aminotransferase (ALT)[5]. Among patients 
with lymphoma and prior HBV infection receiving 
rituximab, 10%-60% exhibit HBV reactivation at a 
median of 3 mo after the last rituximab dose[8,15]. 
Despite 2007-8 guidance from the Centers for Disease 
Control and the American Association for the Study of 
Liver Disease[16] recommending HBV screening before 
immunosuppression, low screening rates persist 
nationally[4,17]. 
In 2013, the FDA reported 32 anti-CD20 Ab-related 
HBV reactivation fatalities occurring up to 12 mo post-
therapy, in whom only 3 (9%) received prophylactic 
HBV antivirals during treatment and follow-up[10]. 
In 2013, the American Society for Clinical Oncology 
(ASCO) recommended universal HBV screening prior 
to anti-CD20 Ab; the 2014 ASCO Quality Oncology 
Practice Initiative reported nearly 70% HBV screening 
rates[10]. HBV screening and antiviral treatment 
decrease reactivation 10-fold and yield cost savings[18]. 
Additionally, antiviral treatment cost-effectively 
decreases lymphoma- and liver-related deaths in those 
with HBV infection[6]. 
With these improved outcomes with HBV antivirals, 
2015 ASCO recommendations prior to anti-CD20 
Ab include: (1) hepatitis B surface antigen (HBsAg) 
and hepatitis B core antibody (HBcAb) screening; (2) 
treating patients with chronic HBV with entecavir or 
tenofovir during anti-CD20 Ab and 6-12 mo following; 
and (3) use of either prophylactic or prompt on-
demand HBV antivirals for HBV reactivation (identified 
by increased HBV DNA or ALT on every 3 mo testing) 
in those with prior HBV (HBsAg-, HBcAb+)[10]. While 
ASCO does not specify care of resolved (HBsAg-, 
HBcAb+, HBsAb+) HBV, prospective controlled 
lymphoma studies of anti-CD20 Ab report 20% HBV 
reactivation rates in resolved HBV without use of 
prophylactic HBV antivirals, resulting in chemotherapy 
interruptions, hepatitis, and reverse seroconversion 
(i.e., HBsAg reappears)[1,11]. These events were 
prevented with prophylactic entecavir treatment[1]. 
Overall, prophylactic antivirals are associated with 
lower HBV reactivation, liver failure and death rates 
compared to on-demand antivirals[8,10]. 
The VHA is the largest single-system United States 
health care provider. Compared to the general United 
States population[2], Veterans exhibit a 2 to 3-fold 
higher prevalence of chronic HBV infection[19,20]. We 
aimed to identify all VA patients initiating anti-CD20 
Ab (2002-2014) to assess the use of HBV serologic 
testing, vaccination, antivirals and the rate and 
timing of hepatitis B-associated complications during 
treatment. 
MATERIALS AND METHODS
Study design and data source
We performed a retrospective cohort study using the 
VHA Corporate Data Warehouse (CDW), a national 
repository of VA electronic medical record data[19]. 
We ascertained patient demographics, inpatient 
and outpatient visits, laboratory results, procedures 
(including hepatitis B vaccination), vital signs, 
pharmacy data, and vital status. VA Vital Status 
mortality data is highly accurate, exhibiting 98% exact 
agreement with dates in the National Death Index[21]. 
Patient population 
All patients initiating anti-CD20 Ab (2002-2014) were 
identified using VHA pharmacy data. Among these, 
those who were followed to death or for at least 12 
mo after completing anti-CD20 Ab were analyzed 
in this study. The analysis was exempted by the 
Durham VAMC Institutional Review Board from review 
as it was performed for VHA quality improvement. 
Informed consent was not needed as only anonymized 
patient information was used in this national quality 
improvement analysis.
Hepatitis B-related variables and their definitions
Pretreatment hepatitis B vaccination at any prior 
time was obtained from CDW vaccination records. 
Pretreatment HBV testing was quantified at any 
preceding time, within the study period, and within 6 
mo of anti-CD20 Ab initiation. However, we identified 
HBV disease categories by serologic testing during 
the study period only[22]. Most (about 90%) VHA 
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DNA and HBeAg data, we were unable to identify 
HBV reactivation by published definitions[4,5,8,15]. The 
rates and timing of health outcomes in the high-
risk period included hepatitis events, liver failure 
and death (overall, cancer-, liver-, or HBV-related). 
Outcomes were compared among the pretreatment 
HBV disease categories and by HBV antiviral use. 
Hepatitis events were defined as ALT > 2 × baseline 
(ALT immediately preceding anti-CD20 Ab) and ALT > 
2 × upper limit normal (ULN) in the high-risk period[8], 
while liver failure was defined as hepatitis and an INR 
≥ 1.5[23]. Information on death and cause of death 
in the high-risk period was retrieved from 2014 vital 
status information. Hepatitis B-associated death met 
the liver failure definition and had no other apparent 
cause of death. Liver-related death was identified by 
International Classification of Diseases, 9th Edition 
(ICD-9) prior to death[24], as was NHL/CLL cancer 
related death (ICD-9 codes 200, 202, and 204.12). 
Other study variables
Age, gender, race, baseline comorbidities, and the anti-
CD20 Ab indication were ascertained at the time of 
anti-CD20 Ab initiation. Baseline comorbidities were 
determined using ICD-9 codes related to cirrhosis, 
decompensated liver disease, hemodialysis-dependent 
renal failure, human immunodeficiency virus (HIV), 
sexually transmitted disease, and alcohol and substance 
abuse.
Statistical analysis
A biomedical statistician performed the statistical 
analyses and completed pre-submission statistical 
review. Baseline patient characteristics were tabulated. 
Statistical analyses were performed using Stata MP-64 
version 13.1 (StataCorp LP, College Station, Texas), 
and differences were considered statistically significant 
when the p-value was less than 0.05. Cumulative 
hepatitis, liver failure, and death after anti-CD20 Ab 
initiation were compared by HBV disease categories (6 
pretreatment HBV disease categories plus acute HBV: 
chronic, past, resolved, acute, negative, vaccinated, 
and unknown) and differences compared using the 
χ 2 test. Mean time to hepatitis peak ALT, liver failure, 
and death relative to anti-CD20 Ab administration and 
follow-up were also compared by HBV disease group. 
RESULTS 
Demographics
We identified 19304 patients who received anti-
CD20 Ab in the VA from 2002-2014, of whom 14887 
had at least 12 mo follow-up after anti-CD20 Ab. 
Most patients were older white males receiving anti-
CD20 Ab with NHL (66%), CLL (24%), or rheumatoid 
arthritis (12%) (Table 1). Comorbid illnesses included 
alcohol or substance abuse, hepatitis C, cirrhosis, 
decompensated liver disease or hemodialysis-
HBV assays were qualitative (or categorical), and as 
normal ranges were not provided in CDW, numerous 
serology results were indeterminate. We divided the 
study population into six pretreatment HBV disease 
categories: definite chronic HBV infection (HBsAg+ for 
more than 6 mo regardless of HBV DNA), likely chronic 
HBV (single pretreatment HBsAg+), past HBV (HBsAg-, 
HBcAb+, HBsAb-)[10], resolved HBV (HBsAg-, HBcAb+, 
HBsAb+)[1,11], likely prior vaccination (isolated HBsAb+, 
HBsAg-, HBcAb-), HBV negative (HBsAg-, HBcAb-) or 
unknown (with no pretreatment HBV serology or those 
who could not be categorized). Reverse seroconversion 
was defined as the reappearance of HBsAg or HBeAg 
in patients with past or resolved HBV[10]. As earlier 
reported, the “high-risk period” was defined as 
the period of anti-CD20 Ab treatment and 12 mo 
follow-up[15]. In patients negative for HBV (HBsAg-, 
HBcAb-) before treatment, acute HBV was defined 
by the appearance of HBsAg+ in the high-risk period. 
Patients with acute, chronic, past or resolved HBV 
were categorized as HBV positive, while HBV negative 
or likely vaccinated patients were categorized as HBV 
negative. 
During the high-risk period, HBV antiviral use 
(adefovir, entecavir, lamivudine, tenofovir, and 
telbivudine) was identified using the pharmacy data 
(yes vs no). HBV antiviral treatment was termed 
“prophylactic” when administered within 3 mo of 
anti-CD20 Ab initiation and “on demand” following 
this period. Due to very limited quantitative HBV 
Table 1  Baseline characteristics and comorbidities and anti-
CD20 antibody treatment indication  n  (%)
Baseline characteristics
Males 18464 (96)
Mean age (range, SE) 66.6 yr (20.3-97.5, 0.0813) 
Median, at risk (range) 478 d (365-4083)
Race  
   White 14520 (76)
   Black or African-American   2460 (12) 
   Hispanic or Latino   878 (5)
   Native Hawaiian or Pacific Islander   171 (1) 
   American Indian or Alaska Native   148 (1)
   Asian     71 (0)
   Missing 1056 (5)
Indication for anti-CD20 antibody treatment 
   Non-hodgkin’s lymphoma    11384 (66.2)
   Chronic lymphocytic leukemia     4,110 (23.9)
   Rheumatoid arthritis     2,151 (12.5)
   Wegener’s granulomatosis   174 (1)
   Microscopic polyangiitis         54 (0.3)
Baseline comorbidities
   Alcohol abuse      4286 (24.9)
   Substance abuse    1485 (8.6)
   Hepatitis C 1369 (8)
   Cirrhosis      808 (4.7)
   Decompensated liver disease      660 (3.8)
   Hemodialysis-dependent renal failure      597 (3.5)
   HIV      234 (1.4)
   Sexually transmitted disease        25 (0.1)
   Total number of patients   19304 (100)
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dependent renal failure (Table 1). 
Hepatitis B testing
Prior to anti-CD20 Ab treatment, 61%-73% had 
HBsAg and HBcAb tested at any time pretreatment 
in 2014 (Figure 1). During the study period, the rates 
of HBsAg and HBcAb testing increased more than 
two-fold (Figure 1) with overall pretreatment HBsAg 
and HBcAb measured in 53% (10224/19304) and 
41% (7903/19304), respectively. In 2014, 43%-49% 
of patients had pretreatment HBsAg and HbcAb 
screening within 6 mo of anti-CD20 Ab initiation (Figure 
1). During the high-risk period for reactivation, < 2% 
(261/14880) had HBV DNA measured.  
Hepatitis B disease categories
In those tested, hepatitis B disease categories (7 
categories including “unknown”) were assessed as: 
definite chronic HBV in 40/10224 (0.4%), likely 
chronic HBV in 127/10224 (1.2%), past HBV in 
326/7903 (4%), resolved HBV in 427/8110 (5%), 
HBV negative in 6002/7903 (76%), likely prior HBV 
vaccination in 628/8110 (7%), and acute HBV in 
0.3% (16/4947) appearing during or after anti-CD20 
Ab treatment. The remaining 11723/19304 (61% of 
overall) patients were termed “unknown,” as missing 
serology or not otherwise categorized. Pretreatment 
HBV DNA was tested in 2% (403/19304) of patients, 
of whom 2% (9/403) were positive and 24% (97/403) 
were indeterminate. At pretreatment baseline, 
HBeAg was tested in 2% (474/19304), of whom 3% 
(12/474) were positive and 29% (139/474) were 
indeterminate. In all HBV categories, 17% or fewer 
received pretreatment HBV vaccination (as determined 
by vaccination records). 
Antiviral treatment during high-risk period for HBV 
reactivation
Across all HBV disease categories, few patients 
receiving HBV antiviral treatment in the high-risk 
period had concomitant HIV infection (ranging 
from 1 in 59 to 2 in 9, or 2% to 22%). Overall HBV 
antiviral use throughout the high risk period ranged 
from 10%-37% in HBV positive patients at risk for 
reactivation (Figure 2); the highest rate of HBV 
antiviral use was 37% in those with definite chronic 
HBV. In the high-risk period, HBV positive patients 
exhibited low and variable rates of HBV antiviral 
treatment throughout the study period (data not 
shown), although most (80%) HBV antivirals were 
administered prophylactically (i.e., started within 3 mo 
of anti-CD20 Ab initiation). 
Acute hepatitis B
Among 16 pretreatment HBV negative patients 
acquiring acute HBV during the high-risk period, the 
mean peak ALT and bilirubin were 10 × ULN (+/- 13 × 
ULN) and 7 × ULN (+/- 10 × ULN), respectively (Figure 
3). In the 25% (3/12) with acute HBV receiving HBV 
antivirals, the mean peak ALT was 19 × ULN (vs 7 
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Figure 1  Proportion of all patients with pretreatment hepatitis B surface antigen (A) and hepatitis B core antibody (B) testing over time. Over the study 
period, pretreatment HBsAg testing within six months of anti-CD20 Ab initiation increased steadily, in parallel with pretreatment HBsAg testing obtained at any time. 
Over the study period, pretreatment HBcAb testing within six months of anti-CD20 Ab initiation steadily increased, in parallel with pretreatment HBcAb testing obtained 
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Figure 2  Hepatitis B antiviral treatment by hepatitis B category. Mean 
hepatitis B antiviral treatment use during anti-CD20 Ab treatment and 12 mo 
follow-up is profiled by hepatitis B category throughout the study period.
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acute HBV exhibited the highest rates of hepatitis 
[83%) 10/12] among all HBV positive patients, and 
experienced a 33% (4/12) all-cause mortality (Figure 
4). Patients with acute HBV exhibited hepatitis and 
death at a mean time of 327 d or more following anti-
CD20 Ab initiation.
Chronic hepatitis B
During the high-risk period, 37% (11/30) patients 
with definite chronic HBV received HBV antivirals and 
exhibited a mean peak ALT and bilirubin of 8 × ULN (+/- 
19 × ULN) and 3 × ULN (+/- 4 × ULN), respectively. In 
contrast, 10% (9/88) with likely chronic HBV received 
antivirals and had a mean peak ALT 4 × ULN (+/- 16 × 
ULN) (Figure 3). Among chronic HBV positive patients, 
those with definite chronic HBV exhibited the highest 
rates of hepatitis [(43%) 13/30], liver failure [(3%) 
1/30] and all-cause mortality [(40%) 12/30], while 
those with likely chronic HBV exhibited lower rates of 
hepatitis [(27%) 24/88], liver failure [(3%) 3/88] and 
overall mortality [(35%) 31/88] (Figures 4 and 5). 
Patients with chronic HBV experienced hepatitis and 
death at a mean time of more than 210 d after anti-
CD20 Ab initiation.
Past and resolved HBV infection
Of patients with past and resolved HBV infection, 23% 
(59/256) and 21% (64/311) received HBV antivirals, 
respectively, and exhibited a mean peak ALT 3-4 × 
ULN (+/- 8 × ULN) (Figure 3). Among these patients, 
those with past HBV exhibited higher rates of hepatitis 
[(39%) 99/256], liver failure [(1%) 3/256] and overall 
mortality [(36%) 93/256], while those with resolved 
HBV exhibited lower rates of hepatitis [(30%) 93/311], 
liver failure [(0.6%) 2/311] and all-cause mortality 
[(35%) 109/311] (Figures 4 and 5). Patients with past 
or resolved HBV developed hepatitis and death at a 
mean time of 278 d or more following anti-CD20 Ab 
initiation.
HBV negative patients
In HBV negative patients, 7% (422/6022) had 
received prior HBV vaccination. HBV antiviral use 
was associated with concomitant HIV infection. HBV 
negative patients experienced a mean peak ALT of 2 
× ULN (+/-8 × ULN) and the lowest rates of hepatitis 
[(24%) 994/4143] and liver failure [(0.6%) 27/4143] 
(Figure 4). These patients had a relatively low all-
cause mortality [(31%) 1292/4143] (Figure 5).
Patients likely vaccinated against HBV infection
Patients likely vaccinated against hepatitis B (with 
isolated HBsAb+) exhibited 2-6-fold higher rates of 
baseline liver-related comorbidities (24% hepatitis C, 
11% cirrhosis and 8% decompensated liver disease), 
relative to those of unknown HBV status (data not 
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Figure 3  Incidence of hepatitis and liver failure by hepatitis B category. 
The incidence of hepatitis and liver failure during anti-CD20 Ab treatment and 
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Figure 4  Mean peak ALT and bilirubin by hepatitis B category. The mean 
peak ALT and bilirubin of patients during anti-CD20 Ab treatment and 12 mo 
follow-up is profiled by hepatitis B category throughout the study period.
Figure 5  Incidence of overall, hepatitis-B associated, liver-related or 
cancer-related mortality by hepatitis B category. The overall, hepatitis-B 
associated, liver-related or cancer-related mortality incidence during anti-CD20 
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peak ALT of 4 × ULN (+/-10 × ULN), low rates of 
hepatitis [(34%) 140/416], liver failure [(1%) 5/416], 
and the lowest overall mortality [(26%) 109/416] 
(Figures 4 and 5).
Unknown HBV status
Patients with unknown HBV infection status (as 
serology missing or incomplete) exhibited the lowest 
rates of baseline comorbidity and pretreatment HBV 
vaccination rates [(2%) 252/11718], a mean peak ALT 
of 2 × ULN (+/-8 × ULN), low rates of hepatitis [(22%) 
2163/9631], liver failure [(0.6%) 53/9631], and a 
moderate overall mortality of [(35%) 3363/9631] 
(Figures 4 and 5). 
Hepatitis significantly higher in HBV positive patients 
Patients with acute, chronic, past or resolved HBV 
infection were categorized as HBV positive, and are 
at risk of HBV reactivation due to the persistence of 
HBV DNA. When compared to HBV negative or likely 
vaccinated patients, the HBV positive patients exhibited 
significantly higher rates of hepatitis (χ 2 = 27.8, p = 
0.001), and nonsignificantly higher rates of liver failure 
and overall mortality. The small numbers of patients on 
HBV antiviral treatment precluded a planned analysis 
of health outcomes by HBV disease category in the 
presence or absence of antiviral treatment. 
Relationship between hepatitis B vaccination and 
overall mortality
Patients with likely prior hepatitis B vaccination (isolated 
HBsAb+ pretreatment) had the lowest overall mortality 
rates (26% [108/416]) (Figure 5). In contrast, pre-
treatment HBV negative patients who developed acute 
HBV during the high-risk period experienced a 33% 
(4/12) mortality rate.
DISCUSSION
In this first 12 year retrospective national VHA 
analysis, we evaluated HBV testing, vaccination, 
treatment and outcomes in nearly 20000 Veterans 
receiving anti-CD20 Ab treatment, largely for NHL or 
CLL. Rates of pretreatment HBV screening within 6 mo 
of anti-CD20 Ab initiation more than doubled over the 
study period. By 2014, most Veterans receiving anti-
CD20 Ab had recent pretreatment HBsAg and HBcAb 
testing and the large majority had testing at any time, 
which compares favorably with the rates reported 
in ASCO quality oncology practices[10]. However, few 
patients susceptible to reactivation had HBV DNA 
testing during anti-CD20 Ab treatment and follow-
up, limiting detection of HBV reactivation. Among 
those with pretreatment HBV testing, 1 in 9 were 
HBV positive and at risk for HBV reactivation - yet, 
only 21% received HBV antivirals during anti-CD20 
Ab treatment and follow-up. As a result, HBV positive 
patients experienced a significantly higher rate of 
hepatitis than those HBV negative - with most events 
occurring within one year of treatment initiation. This 
data aligns with published data reporting the high 
risk period during anti-CD20 Ab treatment and 12 mo 
follow-up[15]. These hepatitis events, as well as related 
morbidity and costs, can be largely prevented with the 
use of safe, effective prophylactic antivirals in all HBV 
positive patients throughout the high-risk period of 
anti-CD20 Ab treatment and 12 mo follow-up[1,7,8,11]. 
Unexpectedly, we identified 16 cases of acute 
hepatitis B in the high-risk period arising in patients 
negative for HBsAg and HBcAb prior to anti-CD20 
Ab initiation. These appear to be the first published 
reports of acute HBV arising de novo during anti-CD20 
Ab therapy - likely as a result of the prolonged B cell 
suppression compromising host immune defense[3]. 
Hepatitis B vaccination substantively decreases the 
risk of acute HBV, even in high-risk adults[25,26]. Yet, 
in the current study, only 2% of the nearly 12000 “at 
risk” HBV unknown and 7% of the 6000 HBV negative 
patients had pretreatment hepatitis B vaccination. 
These rates are comparable to the 6% and 9% HBV 
vaccine immunity rates in Veterans and United States 
adults age 50 or older, respectively[2]. 
The strengths of this analysis include its large size, 
national scope, reliable pharmacy data, relatively high 
rate of HBV testing, identification of acute HBV risk, 
diverse indications for anti-CD20 therapy, and 12 mo 
follow-up of the large majority of patients after anti-
CD20 Ab administration. Study limitations include the 
lack of VHA standardization of HBV serology resulting 
in some indeterminate results, and the predominantly 
qualitative HBV serologies. While HBV reactivation is 
generally identified by logarithmic increases in HBV 
DNA, reverse seroconversion (newly appearing HBeAg 
or HBsAg), or increases in ALT[27], the very limited 
quantified HBV DNA and HBeAg data required us to 
focus our evaluation on hepatitis - which occurs less 
frequently than HBV DNA increases in reactivation[4]. 
Additionally, the effect of HBV antivirals on health 
outcomes was limited by low antiviral treatment rates.
Automated clinical reminders and decision support 
have earlier been demonstrated to increase HBV 
screening and antiviral prophylaxis prior to immuno-
suppressive therapy. For example, to increase HBV 
screening and antiviral prophylaxis in a Spanish 
medical center, computerized physician order entry 
prompts for HBV screening when ordering biologic 
therapies yielded > 90% screening rates, while 
appropriate consultation and prophylactic HBV 
antiviral treatment prevented HBV reactivation[28]. 
As computerized recommendations and follow-on 
treatment algorithms are highly effective in influencing 
physician behavior and prescribing[29], computerized 
decision support may decrease HBV-related disease 
with anti-CD20 Ab treatment in the VHA. 
In conclusion, the VHA now screens most patients 
for HBV before anti-CD20 Ab treatment, yet seldom 
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measures HBV DNA during treatment and therefore, 
likely under-diagnoses HBV reactivation. Increasing 
VHA hepatitis B vaccination rates should diminish the 
risk of acute hepatitis B[26] and its complications during 
anti-CD20 Ab treatment and followup. In HBV positive 
patients, universal use of HBV antiviral treatment 
throughout anti-CD20 Ab treatment and 12 mo follow-
up will likely decrease mortality and enhance quality of 
life. 
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Background
Among patients with lymphoma and prior hepatitis B virus (HBV) infection 
receiving rituximab, 10%-60% exhibit HBV reactivation at a median of 3 mo 
after the last rituximab dose. Pre-rituximab HBV testing and anti-viral treatment 
reduces HBV reactivation 10-fold and decreases lymphoma- and liver-related 
deaths in those with prior HBV infection.
Research frontiers
While the American Society for Clinical Oncology guidelines recommend HBV 
testing and treatment of patients with prior hepatitis B infection during and up to 
12 mo following anti-CD20 antibody therapy, it is unclear how commonly these 
guidelines are followed in the United States Veterans Health Administration. 
Innovations and breakthroughs
This 12 year retrospective cohort study analyzed 19304 Veterans in the United 
States Veterans Health Administration receiving anti-CD20 antibody therapy. 
The authors found that pre-treatment HBV testing increased over the study 
period, yet 37% or fewer received HBV antiviral treatment during anti-CD20 
antibody treatment and 12 mo follow-up.
Applications
Results of this analysis can be shared with providers and used to develop 
electronic health record algorithms to enhance HBV testing and antiviral 
treatment with anti-CD20 antibody therapy and followup. 
Peer-review
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screen patients for HBV before anti-CD20 Ab treatment, and most likely, prior to 
the administration of any immunosuppressive treatment; in order to determine 
if the patient will benefit from HBV vaccination or preventive antiviral treatment. 
This simple measure will reduce the number of HBV-related deaths occurring in 
a number of patients. It is an interesting and relevant study.
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